Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06726421CT.gov Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) | — | Recruiting | — | — | — |
NCT03571438CT.gov Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors | — | Unknown | — | — | — |
NCT01392183CT.gov Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) | — | Completed | — | — | — |
NCT01217931CT.gov Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial | — | Active Not Recruiting | — | — | — |
NCT01184326CT.gov Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | — | Completed | — | — | — |
NCT01012362CT.gov Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Kidney Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pazopanib (this asset) | Sun Yat-sen University | P3 | B · 60 |
| Alpha-Interferon | Dartmouth-Hitchcock Medical Center | P3 | BBB |
| Girentuximab | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Nivestim | National Institutes of Health Clinical Center (CC) | P3 | BB |
| Etoposide | City of Hope Medical Center | P3 | BB |
| Isocyclophosphamide | City of Hope Medical Center | P3 | BB |
| Fluorouracilum | Medical Research Council | P3 | BB |
| Lenvatinib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P4 | BB |
| Axitinib | Stephanie Berg | P4 | BB |
+42 more in the Kidney Cancer cohort
Other indications for Pazopanib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Ovarian Neoplasm | — | P2 | BB · 71 |
| Non-Small Cell Lung Carcinoma | — | P2/3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pazopanib in Kidney Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pazopanib-kidney-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →